Work

A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity

Year: 1999

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v94.10.3307.422k11_3307_3314

Authors: Leo I. Gordon, Mary Young, Edie Weller, Thomas M. Habermann, Jane N. Winter, John Glick, Chirantan Ghosh, Patrick Flynn, Peter A. Cassileth

Institutions: Northwestern University, Mayo Clinic, University of Miami, Dana-Farber Cancer Institute, Sylvester Comprehensive Cancer Center, University of Pennsylvania

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Awards: G1422427855, G2017411191, G286468852, ECOG Clinical Trials, Eastern Cooperative Oncology Group, ECOG Statistical Office

OpenAlex ID: W55214634

FWCI: 3.174

Cites: 44

Cited by: 29

Related to: 10